News | October 30, 2023
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Subscribe To Our Newsletter & Stay Updated
